The effects of hemoadsorption in patients with sepsis-associated persistent severe AKI who require CRRT: A prospective, randomized controlled pilot study
Authors' conclusion
In this pilot trial, hemoadsorption therapy did not significantly reduce 30-day mortality across the entire cohort. However, a post hoc exploratory subgroup analysis suggested a potential association with improved survival in patients with elevated urinary CCL14 levels.
Study context
- Population
- Patients with sepsis-associated persistent severe AKI (S-PAKI) requiring CRRT
- Participants
- 76 patients
- Comparison
- CVVH + hemoadsorption vs conventional CVVH
- CVVH + HAn = 38
- CVVHn = 38reference
- Primary endpoint
- All-cause mortality
- Follow-up
- 30 days
Methodological detailsprospective, single-centre, pilot
- Prospective
- Single-centre
- Pilot
Primary result
As reported in the abstract
P = 0.159
Secondary outcomes
30-day mortality, CCL14 >1.3 ng/ml (post hoc exploratory subgroup)
- Lower mortality risk with CVVH + HA vs CVVH
- Post hoc exploratory subgroup analysis
APACHE II and Sequential Organ Failure Assessment (SOFA) scores, cytokine clearance, hemodynamic status
- Hemoadsorption significantly decreased APACHE II and SOFA scores, enhanced cytokine clearance and improved hemodynamic status
Renal functional prognosis; duration of mechanical ventilation, RRT, ICU stay and hospital stay among survivors
- No significant improvement or shortening with hemoadsorption
Original publication
The effects of hemoadsorption in patients with sepsis-associated persistent severe AKI who require CRRT: A prospective, randomized controlled pilot study. Ann Intensive Care. Published 22 September 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →